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ABSTRACT
Background. Optimal phosphate control is an unmet need in
chronic kidney disease (CKD). High serum phosphate increases
calcification burden and is associated withmortality and cardio-
vascular disease in CKD. Nicotinamide (NA) alone or in combi-
nation with calcium-free phosphate binders might be a strategy
to reduce phosphate levels and calcification and thus impact
cardiovascular disease in CKD.
Methods. We studied the effect of NA alone and in combina-
tion with magnesium carbonate (MgCO3) as a potential novel
treatment strategy. CKD was induced in dilute brown non-
agouti/2 mice by subtotal nephrectomy followed by a high-
phosphate diet (HP) and 7 weeks of treatment with NA,
MgCO3 or their combination. Control mice underwent subtotal
nephrectomy and received an HP or underwent sham surgery
and received standard chow plus NA.
Results. CKD mice showed increased serum fibroblast
growth factor 23 and calcium–phosphate product that was
normalized by all treatment regimes. NA alone increased
soft tissue and vascular calcification, whereas any treatment
with MgCO3 significantly reduced calcification severity in
CKD. While MgCO3 supplementation alone resulted in
decreased calcification severity, it resulted in increased intes-
tinal expression of the phosphate transporters type II so-
dium-dependent phosphate transporter 1 (Pit-1). Combined
therapy of MgCO3 and NA reduced tissue calcification and
normalized expression levels of intestinal phosphate trans-
porter proteins.
Conclusions. In conclusion, the data indicate that NA increases
while MgCO3 reduces ectopic calcification severity. Augmented
expression of intestinal phosphate transporters by MgCO3
treatment was abolished by the addition of NA. However, the
clinical relevance of the latter remains to be explored.
Importantly, the data suggest no benefit of NA regarding treat-
ment of calcification in addition to MgCO3.
Keywords: chronic kidney disease, hyperphosphataemia, nico-
tinamide, phosphate binders, vascular calcification
INTRODUCTION
The number of patients with chronic kidney disease (CKD) and
end-stage renal disease (ESRD) is increasing and the global
prevalence has reached >10% [1]. Cardiovascular morbidity
and mortality are dramatically high in CKD and ESRD [2–4].
Arterial calcification, in media and intima, contributes centrally
to this excess mortality, as it predicts cardiovascular events; it
affects plaque stability and also stiffens the aorta by increasing
afterload and contributing to chronic heart failure [5].
Disturbances of mineral and bone metabolism occur early in
the course of CKD. When the glomerular filtration rate (GFR)
declines, the kidney is unable to maintain phosphate balance
due to reduced urinary phosphate excretion and the develop-
ment of CKD mineral and bone disorder (CKD-MBD).
Changes in CKD-MBD involve serum calcium and phosphate
levels and endocrine axes controlling mineral and bone metab-
olism. The latter include soluble Klotho, fibroblast growth fac-
tor 23 (FGF23), vitamin D and parathyroid hormone as well as
altered concentrations or activity of local inhibitors of calcifica-
tion such as fetuin A and matrix gla protein.
Hyperphosphataemia is an independent predictor of cardio-
vascular disease, cardiovascular calcifications and mortality in
CKD and even mild elevations in serum phosphate may in-
crease the risk of vascular and valvular calcification [6–8].
Phosphate restriction significantly reduced mortality in urae-
mic rats with established vascular calcification [9]. Patients with
CKD and ESRD are commonly prescribed phosphate binders
to control hyperphosphataemia and thus slow down or stop the
progression of vascular and soft tissue calcification [10].
However, phosphate binder therapy results in a high pill bur-
den, and there is an ongoing discussion on the importance of
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the type of phosphate binders for progression of calcification
and improved survival in CKD, that is, calcium-free versus cal-
cium-containing [11, 12]. Importantly, despite various phos-
phate binders on the market, the reduction of serum phosphate
often remains insufficient and many CKD patients still have
hyperphosphataemia [13]. Some phosphate binders contain
magnesium (magnesium carbonate, magnesium hydroxide).
Magnesium-containing binders were shown to reduce vascular
calcification in rats [14, 15]. Also, magnesium has been reported
to show pleiotropic beneficial effects, for example, on cardiac
function and calcification. Hypomagnesaemia is associated
with atrial fibrillation and hypertension [16].
Hypomagnesaemia is common in CKD, often triggered by pro-
teinuria-induced tubular damages [17].
Phosphate absorption in the intestine occurs via passive par-
acellular and active sodium-dependent transporters [18]. The
relative contribution of active phosphate absorption varies be-
tween 30 and 80%, while the passive transport heavily depends
on the intestinal phosphate concentration [19]. The type II so-
dium-dependent phosphate transporter (NaPi-IIb) is the major
contributor to active phosphate transport in the intestine [20].
A low-phosphate diet leads to an increase in the abundance of
the intestinal NaPi-IIb transporters [21]. Similarly, oral phos-
phate binder therapy might result in up-regulation of intestinal
phosphate transporters and thus increased phosphate absorp-
tion might counteract the treatment goal. Nicotinamide (NA)
and nicotinic acid (both forms of niacin) are two available drugs
that inhibit NaPi-IIb. Several small clinical studies have demon-
strated that NA or niacin treatment reduces hyperphosphatae-
mia and pill burden in dialysis patients [22, 23]. The results of
two recent studies [24, 25] do not support stand-alone NaPi-IIb
inhibition with either nicotinic acid or NA to control serum
phosphate in CKD. Here we investigate the influence of NA
compared with the phosphate binder magnesium carbonate
(MgCO3) and a combination of both using a mouse model of
CKD with vascular and soft tissue calcification and in vitro
assays of vascular smooth muscle cells (VSMCs) and Gli1þ pro-
genitor calcification.
MATERIALS AND METHODS
Mice
The animal study was approved by the government authori-
ties (Landesamt fu¨r Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen). For dose finding, healthy dilute brown
non-agouti/2 (DBA/2) mice received NA via drinking water at
three different dosages (150, 300 or 600mg/mL). After 1 week
we analysed inorganic serum phosphate and intestinal NaPi-IIb
expression. For the main study, female DBA/2 mice underwent
5/6 nephrectomy, 10 per group, as described previously [26].
After 1 week of recovery, a pelleted high-phosphate diet (HP)
(1.65% phosphate, 0.95% calcium; Ssniff, Soest, Germany) was
initiated for 7weeks. The diet was either supplemented with 3%
MgCO3 (Sigma-Aldrich, St Louis, MO, USA; #M7179), 600mg/mL
NA (Medice, Iserlohn, Germany) (via drinking water) or in combi-
nation with each other. Control animals underwent a sham sur-
gery. Blood pressure was measured non-invasively by tail vein
occlusion on a CODA monitor (Kent Scientific, Torrington, CT,
USA). After 7weeks, animals were sacrificed.
Biochemistry
Serum urea, creatinine, calcium and phosphate were mea-
sured by clinical laboratory routine (Vitros 250, Ortho Clinical
Diagnostics, Institut fu¨r Versuchstierkunde, Aachen,
Germany). FGF23 was analysed by enzyme-linked immunosor-
bent assay (TECOmedical, Sissach, Switzerland; #60-6300).
Tissue calcium was analysed by colorimetric o-cresolphtha-
lein assay (Randox Laboratories, Crumlin, Northern Ireland).
Therefore, total tissue calcium was mobilized by 10% formic
acid overnight. Absorption was recorded on a Sunrise micro-
plate absorbance reader (Tecan, Ma¨nnedorf, Switzerland) at
550 nm.
Myocardial magnesium was quantified using the BioCat Kit
(BioCat GmbH, Heidelberg, Germany; K385-100-BV) accord-
ing to the manufacturer’s instructions.
Total protein was analysed by the bicinchoninic acid protein
assay kit (Thermo Fisher, Waltham, MA, USA), and absorption
was recorded on the Sunrise microplate absorbance reader
(Tecan).
The fractional excretion of phosphate was calculated by the
formula (phosphateurine  creatinineblood  100)/phosphate-
blood creatinineurine.
Alkaline phosphatase activity was measured by the Biovision
colorimetric kit (Biovision, Milpitas, CA, USA K412-500).
Reverse transcription polymerase chain reaction (RT-PCR)
Ribonucleic acid (RNA) was harvested from RNAlater
(Qiagen, Venlo, The Netherlands; #76104) stabilized tissue by
the RNeasy mini kit (Qiagen; #74104). The RNA concentration
was measured on an Agilent RNA 6000 (Agilent Technologies,
Santa Clara, CA, USA). RT was performed on a thermocycler in
four steps. The quantitative polymerase chain reaction (qPCR)
core kit was applied on a real-time PCR TaqMan System and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as a housekeeping gene. Primers were NaPi-IIb (SLC34A1;
Biomol, Hamburg, Germany; #VMPS-6022), Pit-1 (SLC20A1;
Biomol; #VMPS-5953), NaPi-IIb (sense: CCTGGGACCTGC
CTGAACT, anti-sense: AATGCAGAGCGTCTTCCCTTT)
and GAPDH (sense: AGATGGTGATGGGCTTCCC, anti-
sense: GGCAAATTCAACGGCACAGT).
Von Kossa staining
The localization of calcium deposits was visualized by von
Kossa staining. Briefly, sections were immersed in 1% aqueous
silver nitrate solution for 5min. After washing, samples were in-
cubated in a solution of 5% sodium carbonate and 9.25% for-
malin for 1min. After a second rinse, sections were developed
using sodium thiosulphate (5%) for 5min and counterstained
in 0.1% safranin-O, followed by a final rinse with tap water.
Immunofluorescence
The small intestine was fixed in 4% paraformaldehyde, em-
bedded in paraffin and cut on a rotary microtome. After depar-
affination, slices were stained for NaPi-IIa (SLC34-A1; Biorbyt,
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Cambridge, UK; #orb195991), NaPi-IIb (SLC34-A2; Abcam,
Cambridge, UK; #Ab122431) and Pit-1 (SLC20-A1; Thermo
Fisher; #PA5-28182). A fluorescent secondary antibody was
used to visualize positive staining. Pictures were taken on a
Biorevo microscope (Keyence, Osaka, Japan; BZ-9000E) and
analysed planimetrically by manual counting of the fluores-
cence-positive area.
Cell culture
Human VSMCs were cultured in SMC growth medium 2
(SMC-GM2; PromoCell, Heidelberg, Germany) supplemented
with epidermal growth factor (0.5 ng/mL), insulin (5lg/mL),
basic fibroblast growth factor-B (2ng/mL) and foetal bovine se-
rum (FBS) (5%). They were cultured for up to 21 days in the
presence of either control medium (Dulbecco’s modified
Eagle’s medium, 10% FBS, 1% penicillin/streptomycin) or oste-
ogenic medium (consisting of control medium supplemented
with 10 nM dexamethasone, 10mM b-glycerol phosphate and
100mM l-ascorbate phosphate).
Gli1þ cells were isolated from bone chips of transgenic
Gli1CreER; tdTomato mice as described previously [27] and
cultivated in alpha-MEM, 10% foetal calf serum. For osteogenic
differentiation, StemXVivo medium (R&D Systems,
Minneapolis, MN, USA) was used according to the manufac-
turer’s instructions for 14 days.
Both cell types were treated with either NA (Medice; 10mM,
added directly to the cell culture medium), magnesium
(AppliChem, Darmstadt, Germany; magnesium carbonate,
1mM, added directly to the cell culture medium), magnesium
and NA in combination or N-methyl-2-pyridone-5-carboxa-
mide (2PY) (LGCStandards, Middlesex, UK; N-methyl-2-pyri-
done-5-carboxamide 0.1mM, 10mM, added directly to the cell
culture medium) or N-methyl-4-pyridone-3-carboxamide (4PY)
[Biozol, Eching, Germany; 1,4-Dihydro-1-methyl-4-oxo-3-pyri-
dine carboxamide 0.1mM, 10mM, dissolved at 10mM in di-
methyl sulfoxide (DMSO) versus DMSO control] in addition to
osteogenic medium.Medium was exchanged every other day.
Statistics
We used one-way analysis of variance for comparisons be-
tween groups, followed by Tukey’s multiple comparison test.
Equal variances were tested with Bartlett’s method. The
D’Agostino and Pearson normality test was performed to check
for Gaussian distribution. Significance was defined as P> 0.05.
Echocardiography
Transthoracic echocardiography was performed on a
Vevo 770 (Visualsonics, Toronto, ON, Canada) as described
earlier [28]. Briefly, mice were anaesthetized with isoflurane
(Abbott, Lake Bluff, IL, USA) and placed on a warming plate
at 37C. Breathing and heart rate were monitored continu-
ously. Left ventricular (LV) mass was calculated in the M-
mode in the long axis view from the Devereux formula.
Ejection fraction (EF) as an index for global LV systolic func-
tion was measured by the Simpson method. Stroke volume
was estimated as the difference between the LV end-systolic
and end-diastolic volumes. Pulse-wave velocity in the right
common carotid artery and the abdominal aorta was mea-
sured using the transit-time method in a two-dimensional
mode. In the carotid artery, the proximal pulse-wave signal
was obtained 1mm behind the origin of the subclavian artery,
the distal signal 1mm before the carotid bifurcation. The
transit time was found by subtracting the distal arrival time
between the electrocardiogram R-wave peak and the foot of
velocity upstroke from the similarly determined proximal ar-
rival time [PWV¼Dd/(Ptdist  Ptprox)], where Pt is the
time point of the proximal or distal pulse-wave signal and Dd
is the distance between the two measurements.
RESULTS
Dose-finding experiment of NA in mice
We first sought to establish an optimal dose of NA that
would significantly reduce serum phosphate levels in mice ex-
posed to HP. Therefore DBA/2 wild-type mice received HP
(1.65% phosphorus, 0.95% calcium) with either no treatment or
three different concentrations of NA in drinking water (n¼ 7
mice/group, all females; Figure 1A). Mice were sacrificed at
1week after initiation of the HP diet and NA treatment. The to-
tal NA dosage per mouse was calculated based on the average
drinking amount (mL/mouse/24 h) resulting in an average daily
intake of 43mg NA/kg bodyweight (low dose) versus 70mg/kg
(medium dose) and 124mg/kg (high dose). Only the high-dose
NA resulted in a significant decrease in serum phosphate
(Figure 1B). High-dose NA treatment also showed a tendency
towards a reduced calcium–phosphate product, however, this
did not reach significance (Figure 1C). Of note, we did not ob-
serve any significant changes of alkaline phosphatase activity
and NaPi-IIb expression in the ileum in this dose-finding ex-
periment (Supplementary data, Figure S1).
NA and magnesium in CKD-associated cardiovascular
calcification
We next sought to determine the effect of NA treatment ei-
ther alone or in combination with MgCO3 in a mouse model of
CKD with vascular and soft tissue calcification. For this, female
DBA/2 mice (10 per group) underwent subtotal nephrectomy
followed by HP followed by no treatment (CKD control) or the
addition of either 3% MgCO3 (CKDþMgCO3) or 600mg/mL
NA (CKDþNA) or a combination of both (CKDþMgCO3/NA;
Figure 2A). Mortality in all CKD groups was 10%. Sham sur-
gery followed by standard chow plus NA treatment served as
the control group (sham). As expected, the CKD control mice
had a decreased GFR (Figure 2B). In the CKD mice receiving
MgCO3, the GFR significantly improved. While none of the
treatments resulted in significant reductions in the increased
serum phosphate level in CKD (Figure 2G), the increased cal-
cium–phosphate product was significantly elevated only in the
CKD control group (Figure 2C). Serum calcium levels were
not significantly different between all groups (Supplementary
data, Figure S2A).
Fractional phosphate excretion significantly increased in
the CKD control group compared with the sham group,
whereas MgCO3 treatment in CKD mice or in combination
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with NA (CKDþMgCO3/NA) resulted in reduced fractional
phosphate excretion (Figure 2D). NA treatment in CKD
alone did not show a significant effect on fractional phos-
phate excretion compared with the CKD control group.
MgCO3 treatment doubled serum magnesium in the
CKDþMgCO3 and CKDþMgCO3/NA groups (Figure 2E).
However, we did not observe significant effects on magne-
sium levels in the heart tissue (Supplementary data, Figure
S2B). FGF23 was 10-fold elevated in the CKD control group
compared with the sham group. All treatment groups
showed significantly reduced FGF23 when compared with
the CKD control group (Figure 2F).
NA treatment reduces the magnesium carbonate-
induced increased expression of intestinal NaPi-IIb
We asked whether any of the phosphate modulating and/or
binding treatment regimes affect renal or intestinal expression
of phosphate transporters. In the kidney, we observed a signifi-
cant up-regulation of NaPi-IIb mRNA expression in the CKD
control and CKDþNA groups compared with the sham group
FIGURE 1: Dose finding study of NA in mice with HP. (A) 12-week-old DBA/2 mice (n¼ 7, females) received HP (1.65% phosphate) together
with no treatment (control¼ vehicle) or three different dosages of NA (150, 300 or 600 mg/mL) for 1 week via drinking water. (B) Serum phos-
phate levels at 1 week. (C) Calcium phosphate product at 1 week. *P< 0.05 by one-way analysis of variance with post hoc Tukey test. All data
represent mean6 standard deviation.
FIGURE 2: Treatment regime and effect on serum calcium and phosphate. (A) 12-week-old DBA/2 mice (n¼ 10/group, all females) underwent
sham surgery and received standard chow plus NA (shamþNA) via drinking water or were subjected to 5/6 nephrectomy followed by HP
(1.65% phosphate) with either no treatment (CKD control) or NA (CKDþNA), 3% magnesium carbonate (CKDþMgCO3) or a combination of
both (CKDþMgCO3/NA). Mice were sacrificed at 7 weeks after surgery. Two mice died after surgery in the NA group as well in the magnesium
carbonate group. One mouse died in the combined therapy group. (B) GFR in the different groups at the time point of sacrifice. (C) Calcium–
phosphate product in the different groups at the time point of sacrifice. (D) Fractional phosphate excretion in the different groups at the time
point of sacrifice. (E) Serum magnesium in the different groups at the time point of sacrifice (F) Serum FGF23 in the different groups at the time
point of sacrifice. (G) Serum phosphate (PO24 ) in the different groups at sacrifice. *P< 0.05; **P< 0.001 versus CKD control;
#P< 0.05 versus
sham control; both by one-way analysis of variance with post hoc Tukey test. All data represent mean6 standard deviation.
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FIGURE 3: Effects of treatment regimes on intestinal and renal phosphate transporter expression. (A) mRNA expression of NaPi-IIb in the
kidney. (B) Quantification of the immunofluorescence signal of NaPi-IIb in the kidney. (C) Representative pictures of immunofluorescence
staining of NaPi-IIb in the kidney. (D) mRNA expression of NaPi-IIa in the kidney. (E) Quantification of the immunofluorescence signal of
NaPi-IIa in the kidney. (F) Representative pictures of immunofluorescence staining of NaPi-IIa in the kidney. (G) mRNA expression of Pit-1
in the kidney. (H) Quantification of the immunofluorescence signal of Pit-1 in the kidney. (I) Representative pictures of immunofluorescence
staining of Pit-1 in the kidney. (J) mRNA expression of NaPi-IIb in the ileum. (K) Quantification of the immunofluorescence signal of NaPi-
IIb in the ileum. (L) Representative pictures of immunofluorescence staining of NaPi-IIb in the ileum. (M) mRNA expression of NaPi-IIa in
the ileum. (N) Quantification of the immunofluorescence signal of NaPi-IIa in the ileum. (O) Representative pictures of immunofluorescence
staining of NaPi-IIa in the ileum. (P) mRNA expression of Pit-1 in the ileum. (Q) Quantification of the immunofluorescence signal of Pit-1 in
the ileum. (R) Representative pictures of immunofluorescence staining of Pit-1 in the ileum. *P< 0.05; **P< 0.001 versus CKD control;
#P< 0.05 versus sham control; both by one-way analysis of variance with post hoc Tukey test. All data represent mean6 standard deviation.
All scale bars¼ 100 mM.
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and both MgCO3-treated groups (Figure 3A). Immunostaining
confirmed this finding at the protein level for the CKDþNA
group but also showed increased expression in the
CKDþMgCO3 group (Figure 3B and C). Similar trends were
found in the expression patterns of NaPi-IIa and Pit-1 in the
kidneys within the treatment groups. No significant differences
were found in NaPi-IIa and Pit-1 protein levels (Figure 3E–I).
Importantly, while the mRNA expression of NaPi-IIa, NaPi-
IIb and Pit-1 in the ileum was not significantly different be-
tween groups (Figure 3J, M and P), we observed significantly in-
creased NaPi-IIb and Pit-1 protein expression in the ileum of
CKD mice receiving MgCO3 alone, whereas the addition of NA
completely inhibited this increased expression (Figure 3K, L, Q
and R). We did not detect any significant changes of NaPi-IIa
expression (Figure 3M).
NA increases calcification in CKD while the addition of
magnesium carbonate can inhibit this process
Next we analysed the calcium content in the aorta, heart and
kidneys. As expected, the calcium content per milligram protein
significantly increased in the CKD control group and von
Kossa staining confirmed calcified areas in the heart, vascular
wall and kidney (Figure 4). CKD mice treated solely with NA
(CKDþNA) showed significantly more calcification in the
heart and kidneys compared with the CKD control group.
However, the addition of MgCO3 to the NA regime
(CKDþNA/MgCO3) significantly reduced calcification sever-
ity compared with the CKD control and CKDþNA groups
(Figure 4A–F). Treatment with MgCO3 alone also showed re-
duced calcification severity compared with the CKD control
and CKDþNA groups (Figure 4A–F).
Echocardiography revealed a significantly reduced stroke
volume only in the CKD controls, whereas EF and pulse-wave
velocity of the common carotid artery remained normal in all
CKD groups (Supplementary data, Figure 3A–C).
N-methyl-2-pyridone-5-carboxamide increases dose-
dependent alkaline phosphatase activity in Gli1þ
progenitor cells
Finally, we investigated whether the effect of NA and/or
MgCO3 on calcification severity can be explained by a direct effect
on the cells that drive the calcification process or whether it is
more likely due to an effect on intestinal phosphate absorption
with a subsequently reduced calcium phosphate product. As
VSMCs and their recently discovered adventitial Gli1þ progeni-
tors are the cellular drivers of vascular calcification [3], we tested
the effect of the above-mentioned treatment combinations on cal-
cification severity using in vitro calcification assays of both cell
types. In addition to NA treatment, we also used its activemetabo-
lite 2PY. Osteogenic differentiation medium resulted in increased
alkaline phosphatase activity and increased calcium levels as read-
outs of calcification in VSCMs and Gli1þ cells (Figure 5A–F).
None of the treatment conditions significantly changed these
readouts in VSMCs. Interestingly, in Gli1þ cells exposed to osteo-
genic differentiation medium, alkaline phosphatase activity was
significantly reduced by the addition of NaþMgCO3. However,
10mM 2PY significantly increased alkaline phosphatase activity as
a potential early pro-calcificatory mechanism. We also evaluated
the in vitro effect of another active metabolite of NA, namely 4PY.
Interestingly, 4PY treatment showed reduced osteogenic differen-
tiation of Gli1þ cells with a significant reduction in alkaline phos-
phatase activity (Figure 5A–F). We also observed a tendency
towards reduced calcium deposition in both VSMCs and Gli1þ
cells following 4PY treatment (Figure 5A–F).
DISCUSSION
In this study we analysed the influence of oral NA and/or
MgCO3 on vascular and soft tissue calcification and intestinal
phosphate transporter expression in DBA/2 mice with CKD.
The strength of our study is the multiple treatment approach
combining two different therapies with potential additive effects
and confirming this in vitro. DBA/2mice are particularly suscep-
tible to tissue calcification due to mutation of the hrc (histidine-
rich calcium-binding protein) gene on chromosome 7 [29, 30].
Our most important finding is that although all treatment
regimes showed similar effects on serum phosphate and the cal-
cium–phosphate product, NA treatment alone resulted in in-
creased soft tissue and vascular calcification, whereas the
addition of MgCO3 significantly reduced it in CKD mice.
MgCO3 treatment also resulted in increased intestinal expression
of the phosphate transporters NaPi-IIb and Pit-1. Whether these
changes include functional changes in phosphate transporters
should be analysed in a future study, for example, by measuring
the phosphate passage through ex vivo intestinal membrane
preparations. However, MgCO3 treatment alone resulted in re-
duced calcification severity with and without NA treatment. The
addition of NA normalized the increased levels of intestinal
phosphate transporter expression. Thus our data suggest that a
therapy of MgCO3 might be beneficial, whereas the question of
whether a combined therapy with NA adds additional benefit
remains unclear. According to the double increase of serum
magnesium, we cannot exclude any systemic effects of those
treatments. Given the multiple beneficial effects reported for
supplemental magnesium and the recent report that magnesium
might directly inhibit hydroxyapatite crystal formation [31], the
increased serummagnesium might explain the decreased calcifi-
cation at least partly outside the effect of magnesium carbonate
as a phosphate binder. Because calcium content differed most in
the myocardium, we measured the magnesium content as well.
Cardiac tissue magnesium content remained unchanged.
However, the increased serum magnesium might certainly have
an effect on calcification, which we cannot exclude. Given the
multiple beneficial effects reported for magnesium as a supple-
ment and the recent report that magnesium might directly in-
hibit hydroxyapatite crystal formation [31], the increased serum
magnesium might explain the decreased calcification at least
partly outside of the effect of MgCO3 as a phosphate binder.
Major issues of oral phosphate binders are the high pill bur-
den and adverse effects, mainly gastrointestinal intolerance, and
thus patients often take phosphate binders irregularly, resulting
in decreased dosage. Intestinal adaptation to phosphate binding
therapy with increased expression of phosphate transporters, as
demonstrated in our experiments with MgCO3 treatment,
might result in increased intestinal phosphate absorption and
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thus counteract the treatment goal. In agreement with this con-
clusion, sevelamer treatment in wild-type mice resulted in
higher serum phosphate levels when compared with NaPi-IIb
knockout mice [32].
The addition of NAmight counteract the above intestinal re-
sponse and thus helps to decrease pill burden and phosphate
load. Given a phosphate-lowering monotherapy, NA does not
appear to be acceptable. Thus Malhotra et al. [24] reported only
minor efficacy of extended niacin compared with placebo in a
subgroup analysis of the Atherothrombosis Intervention in
Metabolic Syndrome with low HDL/HIGH Triglycerides trial in
patients with dyslipidaemia and a GFR <60mL/min/1.73 m2.
The trial of Lenglet et al. [25] aimed for non-inferiority and
safety of NA versus sevelamer and reported a comparable de-
crease in serum phosphate in 100 dialysis patients. However, the
criterion for non-inferiority was not met due to a smaller num-
ber of patients being included than planned. Beyond these clini-
cal observations, our data show that NA monotherapy in CKD
can also increase tissue calcification. The reason for this remains
unclear; however, our finding is in line with the observation of
increased cardiac calcium levels in a mouse model of tumoural
calcinosis treated with NA [33]. We failed to obtain a significant
difference in aortic calcium content/vascular calcification in
CKD mice compared with the control group. Therefore we also
investigated VSMC and Gli1þ pericyte calcification in vitro.
Here we evaluated whether the effect of NA on vascular calcifi-
cation severity can be explained by direct effects on the cells that
drive this process. 2PY, the active metabolite of NA, is increased
in CKD patients and has been discussed as a uraemic toxin [34].
Hence we also asked whether 2PY might be involved in the in-
creased calcification severity we have observed in NA-treated
mice. 2PY treatment promoted alkaline phosphatase activity in
calcifying Gli1þ cells. As the calcium content was not increased
by 2PY, we probably identified an early procalcificatory effect of
2PY, which should be analysed further in an animal study. We
also evaluated the effect of 4PY, another active metabolite of
NA. Interestingly, we observed a tendency towards less calcium
deposition and reduced alkaline phosphatase activity in Gli1þ
cells.
We have to point out that major physiological differences
between mice and humans exist with regard to intestinal phos-
phate transport. For example, in humans, NaPi-IIb is mainly
FIGURE 4: Effects of NA and MgCO3 treatment on vascular and soft tissue calcification. (A) Calcium quantification in the aorta. (B)
Representative images of von Kossa–stained section of the aorta. (C) Calcium quantification in the heart. (D) Representative von Kossa–
stained heart images. (E) Quantification of calcium in the kidney. (F) Representative images of von Kossa–stained kidney. *P< 0.05;
**P< 0.001 versus CKD control; #P< 0.05 versus sham control; both by one-way analysis of variance with post hoc Tukey test. All data repre-
sents mean6 standard deviation. Scale bar¼ 100 mM.
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located in the duodenum and jejunum, whereas in mice it is
mainly located in the ileum [35]. Furthermore, in mice, we usu-
ally cannot obtain CKD stages beyond stage 3. Next, our dose-
finding study was performed in healthy mice and not in CKD
mice. The serum phosphate level did not significantly change in
the CKDmice treated with NA and thus it might be that testing
NA in CKD mice would have resulted in a different dosage re-
gime. At 600mg/mL NA, we found a significant reduction of se-
rum phosphate in healthy mice. Of note, the NA dosage used in
this study is approximately 6-fold higher compared with the
dosage used in clinical trials. We can therefore not exclude that
this high dose might have resulted in toxic effects that partly ex-
plain the increased calcification. We did not measure serum
concentration of NA, 2PY or 4PY, which is a limitation of the
study. However, pharmacokinetic data for NA in mice are well
documented [36], providing valuable data to set the dosage for
the in vitro experiments. Another limitation of the study is that
we only focus on one calcification model. DBA/2 mice might be
particularly sensitive to magnesium [37] and therefore other
models will have to be studied to see if the beneficial effects of
MgCO3 can be reproduced. However, in line with our results,
magnesium has already been described to counteract in vitro
smooth muscle cell calcification [28].
Given that our experimental study and two recent clinical
trials did not support the use of niacin and NA alone to control
serum phosphate in CKD patients [23–25], the addition of
MgCO3 might be an option.
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